Alumni of UC Los Angeles (Professional)
Regenica Biosciences, Inc. operates as a hybrid between a clinical stage pharmaceutical company and a government defense contractor. Regenica specializes in the development and commercialization of solutions for serious unmet medical needs and biothreats. Regenica has developed a regulatory strategy that allows for the economically feasible development of historically unprofitable but high social need drugs and vaccines. Regenica is currently seeking FDA approval on an antidote to nerve agent exposure designed to treat any immediate organophosphate toxicity throughout the brain and body while preventing the persisting seizures that recur following exposure.
Primary Industry Sector: Medical Therapeutics
Funding Status: Preseed